Evaluation of two frailty indices, with practical application in a vaccine clinical trial
- PMID: 31157595
- PMCID: PMC6930102
- DOI: 10.1080/21645515.2019.1622974
Evaluation of two frailty indices, with practical application in a vaccine clinical trial
Abstract
Frail older adults are at increased risk of poor clinical outcomes. Frailty assessment is therefore important in clinical trials to understand the benefits and harms of interventions. However, consensus is lacking on how frailty should be assessed.We developed a prospectively specified index using a battery of formal tests and instruments and a retrospectively generated index using medical comorbidities and patient reported outcomes (PROs) within an adjuvanted recombinant zoster vaccine (RZV) trial (NCT02979639). For both frailty indices (FIs), a total deficit score was calculated as the accumulation of deficits and participants were categorized as non-frail, pre-frail and frail. We assessed (1) the feasibility and validity of both FIs; (2) the impact of RZV vaccine reactogenicity by frailty status on Short Form-36 [SF-36] physical functioning (PF) scores.Of 401 participants, aged ≥50 years, 236 (58.9%) were categorized non-frail, 143 (35.7%), pre-frail, and 22 (5.5%) frail using the prospective FI. Corresponding numbers for the retrospective FI were 192 (47.9%), 169 (42.1%) and 40 (10.0%), respectively. Strong concordance was observed between the frailty status assessments (P < .001). The proportion defined as frail increased from 1.5%, to 10.4% in participants aged 50-59, and ≥70 years, respectively, for the prospective FI. Corresponding numbers for the retrospective FI were 3.7%, and 17.2%, respectively. RZV vaccination was associated with a transient, non-clinically meaningful, decrease on the SF-36 PF score in frail participants.Both frailty indices provided similar results. The retrospectively generated FI offers the advantage of being easier to incorporate into vaccine clinical trials of older adults.
Keywords: Varicella-zoster virus; adjuvanted recombinant zoster vaccine; frailty; herpes zoster; older adult; reactogenicity.
Figures



Similar articles
-
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):485-490. doi: 10.1093/gerona/glaa127. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32530462 Free PMC article. Clinical Trial.
-
Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.J Am Geriatr Soc. 2021 Mar;69(3):744-752. doi: 10.1111/jgs.16917. Epub 2020 Nov 16. J Am Geriatr Soc. 2021. PMID: 33197294 Free PMC article. Clinical Trial.
-
An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical Trials.Clin Interv Aging. 2022 Aug 19;17:1261-1274. doi: 10.2147/CIA.S364997. eCollection 2022. Clin Interv Aging. 2022. PMID: 36017192 Free PMC article. Clinical Trial.
-
Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies.Aging Clin Exp Res. 2018 Jul;30(7):693-702. doi: 10.1007/s40520-018-0956-3. Epub 2018 May 2. Aging Clin Exp Res. 2018. PMID: 29721782 Review.
-
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.Expert Rev Vaccines. 2018 Jul;17(7):619-634. doi: 10.1080/14760584.2018.1495565. Epub 2018 Jul 20. Expert Rev Vaccines. 2018. PMID: 30028651 Review.
Cited by
-
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):485-490. doi: 10.1093/gerona/glaa127. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32530462 Free PMC article. Clinical Trial.
-
The role of frailty in shaping social contact patterns in Belgium, 2022-2023.Sci Rep. 2025 Apr 15;15(1):12883. doi: 10.1038/s41598-025-96662-8. Sci Rep. 2025. PMID: 40234637 Free PMC article.
-
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.Hum Vaccin Immunother. 2023 Dec 15;19(3):2278362. doi: 10.1080/21645515.2023.2278362. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37965770 Free PMC article. Review.
-
Patient-reported outcomes in vaccines research: relevance for decision-making.Hum Vaccin Immunother. 2022 Dec 31;18(1):1-8. doi: 10.1080/21645515.2021.1875762. Epub 2021 Feb 19. Hum Vaccin Immunother. 2022. PMID: 33606595 Free PMC article. Review.
-
Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist.Clin Interv Aging. 2021 Apr 28;16:731-738. doi: 10.2147/CIA.S295522. eCollection 2021. Clin Interv Aging. 2021. PMID: 33953551 Free PMC article. Review.
References
-
- Looman WM, Fabbricotti IN, Blom JW, Jansen APD, Lutomski JE, Metzelthin SF, Huijsman R and on behalf of the TOPICS-MDS Research Consortium. The frail older person does not exist: development of frailty profiles with latent class analysis. BMC Geriatr. 2018;18:84. doi:10.1186/s12877-018-0776-5. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous